Search alternatives:
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
1 decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
01 1 » 1 1 (Expand Search), 0 1 (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
1 decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
01 1 » 1 1 (Expand Search), 0 1 (Expand Search)
-
201
-
202
-
203
Overexpression of <i>PF10_0355</i> decreases parasite susceptibility to halofantrine (HFN) and related antimalarials.
Published 2011“…Overexpression of <i>PF10_0355</i> decreases parasite susceptibility to (A) HFN and structurally related (B) mefloquine (MFQ) and (C) lumefantrine (LUM). …”
-
204
-
205
-
206
-
207
Decreased E/I synapse ratio and loss of cortico-LA synaptic plasticity in the absence of coronin 1.
Published 2014“…Scale bar, 2 microns. Data shown are mean values ± SD, <i>p</i><0.01. (C) Hippocampal neurons were labeled using anti-vGLUT1 and anti-vGAT antibodies, followed by Alex Fluor 488 or 568 labeled secondary antibodies, respectively. …”
-
208
Elevated IDO activity in HD mouse brains is decreased by <i>ex-vivo</i> iron chelation.
Published 2021“…<p>Mouse pups were supplemented with carbonyl iron from postnatal days 10–17 and then were sacrificed at 14 weeks of age. <b>A.</b> Striatal IDO activity is increased in N171-82Q HD mice and significantly decreased by <i>ex vivo</i> iron (III) chelation (50 μM deferoxamine). …”
-
209
-
210
CDDO-Me radioprotection decreases with progressive oncogenic manipulations in HBECs and in a matched NSCLC line.
Published 2014“…Immortalized HBECs with (A) lenti-<i>KRas</i><sup>V12</sup>, (B) lenti-<i>KRas</i><sup>V12</sup> and sh<i>p53</i> knockdown, and (C) lenti-<i>KRas</i><sup>V12</sup>, sh<i>p53</i>, and <i>myc</i> overexpression. …”
-
211
-
212
Mean change in incidence and diagnoses if testing rates decrease.
Published 2013“…<p>Change in incidence (A) and diagnoses (B) if testing rates decrease by 30% and 50% relative to the current testing rate.…”
-
213
-
214
-
215
-
216
-
217
-
218
-
219
-
220